AzTrials
AzTrials

Language BarrierENTENTENCT06414772

Evaluation of an E-tool Designed to Facilitate Communication Between Allophone Patients and Pediatricians in Emergency Departments.

A study testing Use of MARTI application in addition with a classical consultation/support in people with Language Barrier, run by Centre Hospitalier Universitaire de Besancon at 2 sites in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

In France, over 21 million people visit emergency departments every year, 10% of whom speak little or no French. The language barrier is a problem for patient safety and quality of care. Ethical and financial aspects are also affected. Unnecessary tests are more frequent, hospital stays more numerous and longer. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Language Barrier
What is being tested?
Use of MARTI application in addition with a classical consultation/support
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
2 sitesFrance
Study dates
Jun 2024to Jun 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adult
  • Person responsible for a child admitted to pediatric emergency.
  • Person with a language barrier.
  • Person speaking one of the 11 languages proposed by MARTI.
  • Signed informed consent indicating that the subject has understood the purpose and procedures of the study and agrees to participate in the study and to abide by the requirements and restrictions inherent in the study.
  • Affiliation with a health insurance

Who cannot join

  • Person who shares a common language with the physician.
  • Illiterate person.
  • Person accompanying a child with a life-threatening emergency.
  • Subject without health insurance.
  • Pregnant women.
  • Subject in the exclusion period of another study or in the "national volunteer file".

Trial locations and contacts

2 sites in 1 country.

Justine Mirete, MD contact

33 3 81 93 31

jmirete@chu-besancon.fr

Jean-Baptiste Pretalli, PhD contact

33 3 81 21 81 27

France2 sites
  • CHU de Besançon

    Besançon, 25000

    Kristina Mouyabi, 33 3 81 21 83 56, kmouyabi@chu-besancon.fr

    Justine Mirete, MD

  • Hôpital Nord Franche-Comté

    Trévenans

    Thibaut Pégeot, MD

Other trials in France

About this study

Official title: Evaluation of an Electronic Tool Designed to Facilitate Communication Between Allophone Patients or Patients With Communication Difficulties and Physicians in Pediatric Emergency Departments.

In France, over 21 million people visit emergency departments every year, 10% of whom speak little or no French. The language barrier is a problem for patient safety and quality of care. Ethical and financial aspects are also affected. Unnecessary tests are more frequent, hospital stays more numerous and longer. Patient's management may be inappropriate. Patients are less satisfied, understand and adhere less to cmanagement and recommendations.

Some solutions are available to the emergency physician, but their contribution is limited. A professional interpreter is reliable and takes cultural aspects into account, but his or her cost is high and availability incompatible with emergency care. Translation by a close relative poses the problem of confidentiality. Telephone interpreting is available at any time, but is expensive and less satisfying than direct interaction. Computerized machine translation is economical and easy to access, but does not take into account all medical terms. It also poses a data protection problem. Phraselators translate predefined phrases with precision, but are time-consuming and unsophisticated.

Read more

In addition, these aids are used during the consultation. They are therefore difficult to combine and take up care time.

This care time is mainly devoted to establishing medical history essential for the diagnosis, prognosis and treatment decisions.

MARTI is a digital tool for pediatric emergency room consultations. Its aim is to enable the emergency physician to start the consultation with a medical history completed autonomously by the parents during their waiting time. Its content has been developed by emergency physicians.

Language and cultural barriers are overcome through the use of simple phrases and pictograms developed with linguists, language schools and Immigrant organizations.

MARTI was used in a pediatric emergency department. Feedback from patients and carers indicates that it is ready to be tested in real-life conditions.

This pilot study is designed to evaluate how MARTI improves communication with an allophone or a person with comprehension difficulties, according to the emergency physician in charge of the consultation.

Being tested
Use of MARTI application in addition with a classical consultation/support

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Use of MARTI application in addition with a classical consultation/supportOther

    Participants will use MARTI in order to establish the medical history during their waiting time.

Study groups in NCT06414772
Study groupRoleWhat they receive
With MARTI e-toolExperimentalNot described
Receives: Other: Use of MARTI application in addition with a classical consultation/support
Without MARTI e-toolNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quality of communication

    The quality of communication will be assessed using a Likert-type scale to be completed by the emergency physician at the end of the consultation (whether MARTI was used or not).

    Originally, Likert scale is a rating scale that assesses opinions, attitudes, or behaviors quantitatively in five point expressed as follows: strongly agree, agree, neutral, disagree, strongly disagree. These points have been kept for the scale of the study, which was adapted with items like "Using MARTI app reduced my anxiety" (for caregivers), "The app is easy to use" (for parents), etc.

    Measured: Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 May 2024
  2. Study startJun 2024 (estimated)
  3. Primary completionJun 2025 (estimated)
  4. Study completionJun 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06414772
Sponsor's protocol ID
2022/739
Acronym
ENTENTE
Status last verified
May 2024
First submitted
10 Jan 2024
Last updated
16 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Use of MARTI application in addition with a classical consultation/support in people with Language Barrier, run by Centre Hospitalier Universitaire de Besancon at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 16 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Justine Mirete, MD (33 3 81 93 31, jmirete@chu-besancon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quality of communication (time frame: Day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in